Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

By sjmartinez • September 27, 2024

Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Tuchayi AM, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. Efficacy and Toxicity of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Sep 26:jnumed.124.267816. doi: 10.2967/jnumed.124.267816. Epub ahead of print. PMID: 39327018.

Tags: Cardiology/Epi, EAP, General Internal Medicine, mCRPC, PSMA PET, Publications, vision

Symptom status and non-calcified plaque burden across CAC strata: insights from AI-based CCTA quantification

Iskander B, Kambalapalli S, Punnanithinont N, Kinninger A, Krishnan S, Ichikawa K, Lakshmanan S, Roy S, Budoff MJ. Symptom status and non-calcified plaque burden across[...]

Defining the Name of the Game in Exercise Oncology: How Do We Incentivize Physical Activity?

Arega E, Dieli-Conwright CM, Yang EH. Defining the Name of the Game in Exercise Oncology: How Do We Incentivize Physical Activity? JACC CardioOncol. 2025 Dec;7(7):829-832.[...]

Estimating the Proportion of Adverse Pregnancy Outcomes Prevented With Improved Early Pregnancy Cardiovascular Health

Borrowman JD, Huang X, Perak AM, Chung JH, Catov JM, Thelilen LH, Bairey Merz CN, Levine LD, Greenland P, Yee LM, Grobman WA, Khan SS,[...]